Title: RNA Interference-Mediated Inhibition of Myc and/or Myb Gene Expression Using Short Interfering Nucleic Acid
Patent Number: 7,659,389
Filed: July 17, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
"This invention relates to compounds, compositions, and methods useful for modulating Myc and/or Myb gene expression using short interfering nucleic acid molecules," the patent's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of Myc and/or Myb gene expression and/or activity by RNA interference using small nucleic acid molecules. … The small nucleic acid molecules are useful in the treatment of cancer and other diseases and disorders."
Title: RNA Interference-Mediated Inhibition of Muscarinic Colinergic Receptor Gene Expression Using Short Interfering Nucleic Acid
Patent Number: 7,659,390
Filed: Sept. 3, 2008
Lead Inventor: James McSwiggen, Sirna Therapeutics (Merck)
The invention, the patent's abstract states, "relates to compounds, compositions, and methods useful for modulating the expression of genes associated with respiratory and pulmonary disease, such as cholinergic muscarinic receptor genes, using short interfering nucleic acid molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of cholinergic muscarinic receptor genes, or other genes involved in pathways of cholinergic muscarinic receptor gene expression and/or activity by RNA interference using small nucleic acid molecules."
Title: Method for the In Vitro Synthesis of Short Double-Stranded RNAs
Patent Number: 7,659,391
Filed: Oct. 30, 2002 PCT Filed: Oct. 30, 2002
Lead Inventor: Marianne Denise De Backer, Janssen Pharmaceutica (Ortho-McNeil-Janssen Pharmaceuticals)
The invention, the patent's abstract states, "relates to the field of synthesis of short double-stranded RNAs. An in vitro transcription method using bacteriophage polymerases and target sequence-specific single-stranded DNA oligonucleotides as templates is disclosed."
The invention "finds particularly advantageous use in the synthesis of short interfering RNAs that have been shown to function as key intermediates in triggering sequence-specific RNA degradation during post-transcriptional gene silencing in plants and RNA interference in invertebrates and vertebrate systems," the abstract notes.
Title: Compositions and Methods of Using siRNA to Knock Down Gene Expression and to Improve Solid Organ and Cell Transplantation
Application Number: 20100028848
Filed: Nov. 30, 2006 PCT Filed: Nov. 30, 2006
Lead Inventor: Marie Denise Parker, Intradigm (Silence Therapeutics)
"This invention describes compositions and methods using siRNA to target various genes expressed in cells of transplanted organs or tissues and/or genes expressed in the host to improve the success of the transplantation," the patent application's abstract states.
Title: shRNA-Mediated Inhibition of Expression of Alpha 1,6-Fucosyltransferase
Application Number: 20100028949
Filed: Dec. 19, 2007 PCT Filed: Dec. 19, 2007
Lead Inventor: Vincent Beuger, Hoffman-La Roche
The invention, the patent application's abstract states, "comprises a method for producing a heterologous polypeptide with a reduced degree of fucose modification in a mammalian cell by cultivating the mammalian cell under conditions suitable for the expression of said heterologous polypeptide, and recovering the heterologous polypeptide from the mammalian cell or the culture, wherein in said mammalian cell the enzymatic activity of alpha 1,6-fucosyltransferase is reduced by means of an shRNA directed against alpha 1,6-fucosyltransferase mRNA."
Title: Retroviral Vectors for Delivery of Interfering RNA
Application Number: 20100028996
Filed: Oct. 7, 2009
Lead Inventor: Dorre Grueneberg, Aventis Pharmaceuticals (Sanofi-Aventis)
The patent application, its abstract states, claims "retroviral vectors for delivering interfering RNA into cells."
Title: RNAi-Expression Constructs
Application Number: 20100028998
Filed: Feb. 3, 2006 PCT Filed: Feb. 3, 2006
Lead Inventor: Petrus Roelvink, Benitec
The invention "provides compositions and methods suitable for expressing 1-x RNAi agents against a gene or genes in cells, tissues, or organs of interest in vitro and in vivo so as to treat diseases or disorders," according to the patent application's abstract.
Title: System and Methods for Identifying miRNA Targets and for Altering miRNA and Target Expression
Application Number: 20100029003
Filed: Jan. 21, 2009
Lead Inventor: David Bartel, Whitehead Institute for Biomedical Research
The invention "generally relates to microRNAs such as vertebrate microRNA, for example, mammalian miRNA," according to the patent application's abstract. "Various aspects of the invention are directed to the detection, production, or expression of miRNA. In one aspect, the invention provides systems and methods for identifying targets of miRNA sequences. For instance, in one embodiment, gene sequences comprising UTRs are compared with miRNA sequences to determine the degree of interaction, for example, by determining a free energy measurement between the miRNA sequence and the UTR, and/or by determining complementarity between at least a portion of the miRNA sequence and the UTR.
"In another aspect, the invention is directed to the regulation of gene expression using miRNA," the abstract states. "For example, gene expression within a cell may be altered by exposing the cell to an oligonucleotide comprising a sequence that is substantially antisense to at least a portion of an miRNA region of the gene, for example, antisense to a 6-mer or 7-mer portion of the miRNA.
"In still another aspect, the invention is directed to the treatment of cancer," it adds. "For instance, in one set of embodiments, an isolated oligonucleotide comprising a sequence that is substantially antisense to an miRNA, or a portion of an miRNA, is administered to a subject having or being at risk of cancer. Yet other aspects of the invention are directed to compositions or kits including oligonucleotides comprising a sequence that is substantially antisense to an miRNA or a portion of an miRNA, methods of promoting any of the above aspects, or the like."
Title: shRNA Library
Application Number: 20100029505
Filed: Aug. 1, 2008
Lead Inventor: Donald Payan, Rigel Pharmaceuticals
The patent application, its abstract states, relates to "a library of nucleic acid vectors, as well as a method for making the same."
Title: siRNA Targeting Survivin
Application Number: 20100029510
Filed: Sept. 10, 2009
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Through these methodologies, one can select siRNA that target genes, including survivin."
Title: Treatment or Prevention of Oto-Pathologies by Inhibition of Pro-Apoptotic Genes
Application Number: 20100029746
Filed: July 1, 2009
Inventor: Elena Feinstein, Quark Pharmaceuticals
"The invention relates to one or more inhibitors, in particular siRNAs, which down-regulate the expression of human pro-apoptotic genes," the patent application's abstract states. "The invention also relates to a pharmaceutical composition comprising the compound, or a vector capable of expressing the compound, and a pharmaceutically acceptable carrier. The … invention also contemplates a method of treating or preventing the incidence or severity of hearing impairment or balance impairment, particularly hearing impairment associated with cell death of the inner ear hair cells or outer ear hair cells, comprising administering to the patient the pharmaceutical composition in a therapeutically effective dose so as to thereby treat the patient."